Literature DB >> 30810118

EPOS2020: development strategy and goals for the latest European Position Paper on Rhinosinusitis.

W Fokkens1, M Desrosiers2, R Harvey3, C Hopkins4, J Mullol5, C Philpott6, I Alobid7, W T Anselmo-Lima8, C Bachert9, F Baroody10, M Bernal-Sprekelsen11, C von Buchwald12, A Cervin13, N Cohen14, J Constantinidis15, L De Gabory16, R Douglas17, P Gevaert18, A Hafner19, P Hellings20, G Joos21, L Kalogjera22, R Kern23, A Knill24, J Kocks25, B N Landis26, J Limpens27, S Lebeer28, O Lourenco29, P M Matricardi30, C Meco31, L O Mahony32, S Reitsma1, D Ryan33, R Schlosser34, B Senior35, T Smith36, T Teeling37, P V Tomazic38, S Toppila-Salmi39, D Y Wang40, D Wang41, L Zhang42, V Lund43.   

Abstract

BACKGROUND: The European Position Papers on Rhinosinusitis from 2005, 2007 and 2012 have had a measurable impact on the way this common condition with high impact on quality of life is managed around the world. EPOS2020 will be the latest iteration of the guideline, addressing new stakeholders and target users, presenting a summary of the latest literature and evolving treatment modalities, and formulating clear recommendations based on all available evidence.
METHODOLOGY: Based on the AGREE II framework, this article demonstrates how the EPOS2020 steering group will address six key areas to ensure consistency in quality and presentation of information in the latest rhinosinusitis clinical practice guideline: scope and purpose; stakeholder involvement; rigour of development; clarity of presentation; recommendations and applicability; editorial independence.
RESULTS: By analysing the guidance from AGREE II, we formulated a detailed development strategy for EPOS2020. We identify new stakeholders and target users and ratify the importance of patient involvement in the latest EPOS guideline. New and expanded areas of research to be addressed are highlighted. We confirm our intention to use mixed methodologies, combining evidence-based medicine with real life studies; when no evidence can be found, use Delphi rounds to achieve clear, inclusive recommendations. We also introduce new concepts for dissemination of the guideline, using Internet and social media to improve accessibility.
CONCLUSION: This article is an introduction to the EPOS2020 project, and presents the key goals, core stakeholders, planned methodology and dissemination strategies for the latest version of this influential guideline.

Entities:  

Mesh:

Year:  2019        PMID: 30810118     DOI: 10.4193/Rhin19.080

Source DB:  PubMed          Journal:  Rhinology        ISSN: 0300-0729            Impact factor:   3.681


  9 in total

1.  Artificial intelligence processing electronic health records to identify commonalities and comorbidities cluster at Immuno Center Humanitas.

Authors:  Pierandrea Morandini; Maria Elena Laino; Giovanni Paoletti; Alessandro Carlucci; Tobia Tommasini; Giovanni Angelotti; Jack Pepys; Giorgio Walter Canonica; Enrico Heffler; Victor Savevski; Francesca Puggioni
Journal:  Clin Transl Allergy       Date:  2022-06-08       Impact factor: 5.657

Review 2.  Formation of nasal polyps: The roles of innate type 2 inflammation and deposition of fibrin.

Authors:  Tetsuji Takabayashi; Robert P Schleimer
Journal:  J Allergy Clin Immunol       Date:  2020-03       Impact factor: 10.793

3.  Broncalt®, class II medical device, in patients with acute upper airways disease: a survey in clinical practice.

Authors:  Gian Franco Cupido; Matteo Gelardi; Ignazio La Mantia; Salvo Emanuele Aragona; Claudio Vicini; Giorgio Ciprandi; Italian Study Group On Inflammatory Otorhinolaryngological Disorders
Journal:  Acta Biomed       Date:  2019-07-10

4.  Clinical outcome of endonasal endoscopic prelacrimal approach in managing different maxillary pathologies.

Authors:  Yu Hsuan Lin; Wei-Chih Chen
Journal:  PeerJ       Date:  2020-01-03       Impact factor: 2.984

5.  Maximising recruitment to a randomised controlled trial for chronic rhinosinusitis using qualitative research methods: the MACRO conversation study.

Authors:  Clare McDermott; Jane Vennik; Carl Philpott; Steffi le Conte; Mike Thomas; Caroline Eyles; Paul Little; Helen Blackshaw; Anne Schilder; Claire Hopkins
Journal:  Trials       Date:  2021-01-13       Impact factor: 2.279

6.  Case Report: Acupuncture is an effective treatment for olfactory dysfunction in the post COVID-19 condition.

Authors:  Akira Morita; Aya Murakami; Takushu Uchihara; Noriyuki Ohashi; Koichi Ryu; Yuki Watanabe; Sadayuki Ochi; Kazuho Okudaira; Yoshiro Hirasaki; Takao Namiki
Journal:  Front Neurol       Date:  2022-08-23       Impact factor: 4.086

7.  Turkish Guideline for Diagnosis and Treatment of Allergic Rhinitis (ART).

Authors:  Mustafa Cenk Ecevit; Müge Özcan; İlknur Haberal Can; Emel Çadallı Tatar; Serdar Özer; Erkan Esen; Doğan Atan; Sercan Göde; Çağdaş Elsürer; Aylin Eryılmaz; Berna Uslu Coşkun; Zahide Mine Yazıcı; Mehmet Emre Dinç; Fatih Özdoğan; Kıvanç Günhan; Nagihan Bilal; Arzu Yasemin Korkut; Fikret Kasapoğlu; Bilge Türk; Ela Araz Server; Özlem Önerci Çelebi; Tuğçe Şimşek; Rauf Oğuzhan Kum; Mustafa Kemal Adalı; Erdem Eren; Nesibe Gül Yüksel Aslıer; Tuba Bayındır; Aslı Çakır Çetin; Ayşe Enise Göker; Işıl Adadan Güvenç; Sabri Köseoğlu; Gül Soylu Özler; Ethem Şahin; Aslı Şahin Yılmaz; Ceren Güne; Gökçe Aksoy Yıldırım; Bülent Öca; Mehmet Durmuşoğlu; Yunus Kantekin; Süay Özmen; Gözde Orhan Kubat; Serap Köybaşı Şanal; Emine Elif Altuntaş; Adin Selçuk; Haşmet Yazıcı; Deniz Baklacı; Atılay Yaylacı; Deniz Hancı; Sedat Doğan; Vural Fidan; Kemal Uygur; Nesil Keleş; Cemal Cingi; Bülent Topuz; Salih Çanakçıoğlu; Metin Önerci
Journal:  Turk Arch Otorhinolaryngol       Date:  2021-05

8.  Intranasal Corticosteroids: Patient Administration Angles and Impact of Education.

Authors:  Sara Treat; Charles S Ebert; Zainab Farzal; Saikat Basu; Adam M Zanation; Brian D Thorp; Julia S Kimbell; Brent A Senior; Adam J Kimple
Journal:  Rhinol Online       Date:  2020-11-08

9.  Acupuncture is associated with a positive effect on odour discrimination in patients with postinfectious smell loss-a controlled prospective study.

Authors:  Tanja Drews; Thomas Hummel; Bettina Rochlitzer; Bettina Hauswald; Antje Hähner
Journal:  Eur Arch Otorhinolaryngol       Date:  2021-05-25       Impact factor: 2.503

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.